ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

554

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

July 15, 2024

Study Completion Date

July 15, 2024

Conditions

Alzheimer DiseaseDementia of Alzheimer Type

Interventions

DRUG

ATH-1017

Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

DRUG

Placebo

Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe

Trial Locations (1)

University of Rochester-AD-CARE Program, Rochester